- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 458989, 10 pages
Characterization of Schizophrenia Adverse Drug Interactions through a Network Approach and Drug Classification
1Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
2Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN 37232, USA
3Mental Health Service Line, Washington VA Medical Center, 50 Irving St. NW, Washington, DC 20422, USA
4Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA 23298, USA
5Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA
6Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Received 5 July 2013; Accepted 8 August 2013
Academic Editor: Bairong Shen
Copyright © 2013 Jingchun Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- B. A. Ellenbroek, “Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?” Neuropharmacology, vol. 62, no. 3, pp. 1371–1380, 2012.
- H. Y. Meltzer, “Update on typical and atypical antipsychotic drugs,” Annual Review of Medicine, vol. 64, pp. 393–406, 2013.
- K. S. Nandra and M. Agius, “The differences between typical and atypical antipsychotics: the effects on neurogenesis,” Psychiatria Danubina, vol. 24, supplement 1, pp. S95–S99, 2012.
- J. Sokal, E. Messias, F. B. Dickerson et al., “Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services,” Journal of Nervous and Mental Disease, vol. 192, no. 6, pp. 421–427, 2004.
- D. C. Goff, C. Cather, A. E. Evins et al., “Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists,” Journal of Clinical Psychiatry, vol. 66, no. 2, pp. 183–273, 2005.
- M. Zink, S. Englisch, and A. Meyer-Lindenberg, “Polypharmacy in schizophrenia,” Current Opinion in Psychiatry, vol. 23, no. 2, pp. 103–111, 2010.
- S. P. Dunn, D. R. Holmes Jr., and D. J. Moliterno, “Drug-drug interactions in cardiovascular catheterizations and interventions,” JACC: Cardiovascular Interventions, vol. 5, pp. 1195–1208, 2012.
- M. Huber, M. Kolzsch, R. Stahlmann, et al., “Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma,” Drugs & Aging, vol. 30, pp. 31–38, 2013.
- J. Lees and A. Chan, “Polypharmacy in elderly patients with cancer: clinical implications and management,” The Lancet Oncology, vol. 12, no. 13, pp. 1249–1257, 2011.
- C. D. Scripture and W. D. Figg, “Drug interactions in cancer therapy,” Nature Reviews Cancer, vol. 6, no. 7, pp. 546–558, 2006.
- J. Kuhlmann and W. Mück, “Clinical-pharmacological strategies to assess drug interaction potential during drug development,” Drug Safety, vol. 24, no. 10, pp. 715–725, 2001.
- D. S. Tatro, Drug Interaction Facts, Facts & Comparisons, 2012.
- R. R. Conley and D. L. Kelly, “Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients,” Psychopharmacology Bulletin, vol. 40, no. 1, pp. 77–97, 2007.
- N. B. Sandson, S. C. Armstrong, and K. L. Cozza, “An overview of psychotropic drug-drug interactions,” Psychosomatics, vol. 46, no. 5, pp. 464–494, 2005.
- M. A. Raggi, R. Mandrioli, C. Sabbioni, and V. Pucci, “Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions,” Current Medicinal Chemistry, vol. 11, no. 3, pp. 279–296, 2004.
- M. Bubser and A. Y. Deutch, “Differential effects of typical and atypical antipsychotic drugs on striosome and matrix compartments of the striatum,” European Journal of Neuroscience, vol. 15, no. 4, pp. 713–720, 2002.
- J. Sun, H. Xu, and Z. Zhao, “Network-assisted investigation of antipsychotic drugs and their targets,” Chemistry & Biodiversity, vol. 9, pp. 900–910, 2012.
- C. Knox, V. Law, T. Jewison et al., “DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs,” Nucleic Acids Research, vol. 39, no. 1, pp. D1035–D1041, 2011.
- D. S. Wishart, C. Knox, A. C. Guo et al., “DrugBank: a knowledgebase for drugs, drug actions and drug targets,” Nucleic Acids Research, vol. 36, no. 1, pp. D901–D906, 2008.
- D. S. Wishart, C. Knox, A. C. Guo et al., “DrugBank: a comprehensive resource for in silico drug discovery and exploration,” Nucleic Acids Research, vol. 34, pp. D668–D672, 2006.
- World Health Organization (WHO), The Anatomical Therapeutic Chemical, Classification System, 2003.
- M. Kanehisa, S. Goto, Y. Sato, M. Furumichi, and M. Tanabe, “KEGG for integration and interpretation of large-scale molecular data sets,” Nucleic Acids Research, vol. 40, pp. D109–D114, 2012.
- A.-L. Barabási and Z. N. Oltvai, “Network biology: understanding the cell's functional organization,” Nature Reviews Genetics, vol. 5, no. 2, pp. 101–113, 2004.
- P. Shannon, A. Markiel, O. Ozier et al., “Cytoscape: a software Environment for integrated models of biomolecular interaction networks,” Genome Research, vol. 13, no. 11, pp. 2498–2504, 2003.
- J. M. Bland and D. G. Altman, “Multiple significance tests: the Bonferroni method,” British Medical Journal, vol. 310, no. 6973, article 170, 1995.
- D. D. Short, J. M. Hawley, and M. F. McCarthy, “Management of schizophrenia with medical disorders: cardiovascular, pulmonary, and gastrointestinal,” Psychiatric Clinics of North America, vol. 32, no. 4, pp. 759–773, 2009.
- J. R. Horn and P. D. H. Hansten, “Prophylactic dose adjustments in management of drug interactions,” Pharmacy Times, vol. 77, no. 11, 2011.
- Truven Health Analytics Inc, “Micromedex Healthcare Series,” 2013.
- D. M. Roden, H. Xu, J. C. Denny, and R. A. Wilke, “Electronic medical records as a tool in clinical pharmacology: opportunities and challenges,” Clinical Pharmacology & Therapeutics, vol. 91, pp. 1083–1086, 2012.
- J. F. Carlquist and J. L. Anderson, “Pharmacogenetic mechanisms underlying unanticipated drug responses,” Discovery Medicine, vol. 11, pp. 469–478, 2011.
- J. Lamb, E. D. Crawford, D. Peck et al., “The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease,” Science, vol. 313, no. 5795, pp. 1929–1935, 2006.
- S. F. Kingsmore, I. E. Lindquist, J. Mudge, D. D. Gessler, and W. D. Beavis, “Genome-wide association studies: progress and potential for drug discovery and development,” Nature Reviews Drug Discovery, vol. 7, no. 3, pp. 221–230, 2008.